← Back to Search

CAR T-cell Therapy

CAR-Macrophages + Pembrolizumab for HER2 Positive Cancer

Phase 1
Waitlist Available
Research Sponsored by Carisma Therapeutics Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
HER2-positive recurrent or metastatic solid tumors for which there are no available curative treatment options
Must not have
Subjects who have had an allogeneic tissue/solid organ transplant
Diagnosis of immunodeficiency or chronic exposure to systemic corticosteroid therapy or any other form of immunosuppressive therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights

Summary

This trial is testing a new cancer treatment involving CAR macrophages (a type of white blood cell) and HER2 overexpressing solid tumors (a type of cancer).

Who is the study for?
This trial is for adults with HER2-positive solid tumors that have no curative treatments left. They must have tried all standard therapies, and if they have breast or gastric cancers, also failed HER2-targeted drugs. Participants need to be relatively healthy (ECOG 0-1) and able to undergo biopsies. Those with heart issues, active autoimmune diseases, organ transplants, certain infections or severe allergies to the study drug can't join.Check my eligibility
What is being tested?
The trial is testing a new therapy called CT-0508 in combination with an existing cancer drug named Pembrolizumab on patients with various types of advanced cancer that overexpresses HER2 protein. It's a phase 1 study which means it's the first time this treatment is being used in humans to check its safety.See study design
What are the potential side effects?
Possible side effects include immune system reactions leading to inflammation in different parts of the body, infusion-related reactions from receiving drugs through veins, fatigue, potential worsening of pre-existing autoimmune conditions and allergic responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am fully active or can carry out light work.
Select...
My cancer is HER2-positive, has returned or spread, and cannot be cured with available treatments.
Select...
My breast or stomach cancer did not respond to previous HER2 treatments.
Select...
I am willing and able to have a biopsy.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have received an organ or tissue transplant from another person.
Select...
I have an immune system disorder or I'm on long-term steroids or other drugs that weaken my immune system.
Select...
I do not have HIV, active hepatitis B or C.
Select...
I have or had lung inflammation that needed steroids.
Select...
I have untreated brain metastases or cancer in my brain's lining.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Assess the feasibility of manufacturing CT-0508 by describing the percentage of products passing release criteria.
Assess the safety and tolerability of CT-0508 by estimating the frequency and severity of adverse events in subjects with HER2 overexpressing solid tumors.
Assess the safety and tolerability of CT-0508 in combination with pembrolizumab by estimating the frequency and severity of adverse events in subjects with HER2 overexpressing solid tumors (CT-0508 and pembrolizumab substudy only)
Secondary outcome measures
Estimate progression-free survival (PFS).
Estimate the objective response rate (ORR), according to RECIST v1.1, of at least 1 dose of CT-0508 among subjects with HER2 overexpressing solid tumors.

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183
21%
Fatigue
13%
Nausea
11%
Back pain
9%
Shortness of Breath
9%
Anemia
9%
Abdominal pain
9%
Diarrhea
7%
Pneumonia
7%
Kidney Injury and/or Infection
7%
Dyspnea
7%
Weight Loss
5%
Pneumothorax
5%
Malnutrition, Hypercalcemia and Weakness
5%
Intractable pain, back pain, hip pain
5%
Activated partial thromboplastin time prolonged
4%
Pleural effusion
4%
Atrial fibrillation with rapid ventricular response
2%
Thrombocytopenia
2%
Respiratory failure
2%
Skin rash
2%
colitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Arm

Trial Design

4Treatment groups
Experimental Treatment
Group I: Intraperitoneal AdministrationExperimental Treatment1 Intervention
All cohorts will receive the full dose manufactured per patient. Cohorts 1-3 will undergo intrasubject dose escalations of IP administration as follows: Cohort 1 up to 500 million total cells on Day 1, up to 1 billion total cells on Day 3 and up to 1.5 billion total cells on Day 5. Cohort 2 up to 1.5 billion total cells on Day 1, up to 2 billion total cells on Day 3 and any remaining cells on Day 5. Cohort 3 up to 2.5 billion total cells on Day 1 and up to 2.5 billion total cells on Day 3. Cohort 4 will 1 dose on Day 1 of up to 5 billion total cells.
Group II: Group 1 and Group 2Experimental Treatment1 Intervention
Both groups will receive the full dose manufactured per patient. Group 1 will undergo intra subject dose escalation of IV administrations of up to 500 million total cells on Day 1, up to 1.5 billion total cells on Day 3, and up to 3.0 billion total cells on Day 5. Group 2 will receive the full dose IV on Day 1 of up to 5 billion cells total.
Group III: CT-0508 in Combination with PembrolizumabExperimental Treatment2 Interventions
All regimen levels will receive the full dose manufactured per patient up to 5 billion total cells. Regimen Levels 1 and 2 will undergo intrasubject dose escalations of IV administration as follows: Regimen Level 1: up to 500 million total cells on Day 1, up to 1.5 billion total cells on Day 3, and up to 3.0 billion total cells on Day 5 plus pembrolizumab 200 mg q3w starting on Day 8. Regimen Level 2: up to 500 million total cells on Day 1, up to 1.5 billion total cells on Day 3, and up to 3.0 billion total cells on Day 5 plus pembrolizumab 200 mg q3w starting on Day 1. Regimen Level 3 will receive the full dose IV on Day 1 of up to 5 billion total cells plus pembrolizumab 200 mg q3w starting on Day 1.
Group IV: 89[Zr]radiolabeled CT-0508Experimental Treatment1 Intervention
89[Zr] radiolabeled group will receive a full dose IV on Day 1 of up to 500 million total cells of 89[Zr] radiolabeled CT-0508 and non-radiolabeled CT-0508 of up to 4.5 billion total cells (Univ of Penn Abramson Cancer Center only).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
2017
Completed Phase 2
~2010

Find a Location

Who is running the clinical trial?

Carisma Therapeutics IncLead Sponsor
1 Previous Clinical Trials
6 Total Patients Enrolled
Jeanett WetzelStudy DirectorCarisma Therapeutics
Ramona Swaby, MDStudy DirectorCarisma Therapeutics

Media Library

CAR-macrophages (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04660929 — Phase 1
Breast Cancer Research Study Groups: 89[Zr]radiolabeled CT-0508, CT-0508 in Combination with Pembrolizumab, Group 1 and Group 2, Intraperitoneal Administration
Breast Cancer Clinical Trial 2023: CAR-macrophages Highlights & Side Effects. Trial Name: NCT04660929 — Phase 1
CAR-macrophages (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04660929 — Phase 1
Breast Cancer Patient Testimony for trial: Trial Name: NCT04660929 — Phase 1
~5 spots leftby Dec 2024